128 related articles for article (PubMed ID: 25043451)
21. Human relevance of NRAS/BRAF mouse melanoma models.
Conde-Perez A; Larue L
Eur J Cell Biol; 2014; 93(1-2):82-6. PubMed ID: 24342721
[TBL] [Abstract][Full Text] [Related]
22. Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.
Leung GP; Feng T; Sigoillot FD; Geyer FC; Shirley MD; Ruddy DA; Rakiec DP; Freeman AK; Engelman JA; Jaskelioff M; Stuart DD
Mol Cancer Res; 2019 Jan; 17(1):199-211. PubMed ID: 30201825
[TBL] [Abstract][Full Text] [Related]
23. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H; Goel V; Wu H; Yang G; Haluska FG
J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
[TBL] [Abstract][Full Text] [Related]
24. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
25. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
26. On oncogenic BRAF, melanomagenesis and organ transplant recipients--"the more we know, the less we understand".
Mahalingam M
Eur J Dermatol; 2010; 20(2):143. PubMed ID: 20007066
[No Abstract] [Full Text] [Related]
27. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
28. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
29. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches.
Palmieri G; Colombino M; Casula M; Manca A; Mandalà M; Cossu A;
Curr Oncol Rep; 2018 Sep; 20(11):86. PubMed ID: 30218391
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
32. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
[TBL] [Abstract][Full Text] [Related]
33. High frequency of BRAF mutations in nevi.
Pollock PM; Harper UL; Hansen KS; Yudt LM; Stark M; Robbins CM; Moses TY; Hostetter G; Wagner U; Kakareka J; Salem G; Pohida T; Heenan P; Duray P; Kallioniemi O; Hayward NK; Trent JM; Meltzer PS
Nat Genet; 2003 Jan; 33(1):19-20. PubMed ID: 12447372
[TBL] [Abstract][Full Text] [Related]
34. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.
Patton EE; Widlund HR; Kutok JL; Kopani KR; Amatruda JF; Murphey RD; Berghmans S; Mayhall EA; Traver D; Fletcher CD; Aster JC; Granter SR; Look AT; Lee C; Fisher DE; Zon LI
Curr Biol; 2005 Feb; 15(3):249-54. PubMed ID: 15694309
[TBL] [Abstract][Full Text] [Related]
36. Imaging Mass Spectrometry for the Classification of Melanoma Based on
Casadonte R; Kriegsmann M; Kriegsmann K; Streit H; Meliß RR; Müller CSL; Kriegsmann J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982192
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
[TBL] [Abstract][Full Text] [Related]
38. Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
Datar I; Kalpana G; Choi J; Basuroy T; Trumbly R; Chaitanya Arudra SK; McPhee MD; de la Serna I; Yeung KC
PLoS One; 2019; 14(4):e0204387. PubMed ID: 30995246
[TBL] [Abstract][Full Text] [Related]
39. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
[TBL] [Abstract][Full Text] [Related]
40. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.
Platz A; Egyhazi S; Ringborg U; Hansson J
Mol Oncol; 2008 Apr; 1(4):395-405. PubMed ID: 19383313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
